SCHEMBL702946

SCHEMBL702946

CC(C)C1CC(=O)OC1=O

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13435215 0.86 SMN1; SMN2 (0.33) SMN1; SMN2ALDH1A1TSHR
SCHEMBL14154954 0.82 SMN1; SMN2 (0.31) SMN1; SMN2ALDH1A1TSHR
SCHEMBL12651044 0.79 ACE (0.36) ALDH1A1TSHR
SCHEMBL18464732 0.79 PIK3CD (0.32)
SCHEMBL13335235 0.79 THRB (0.33)
SCHEMBL17363799 0.78
SCHEMBL11758655 0.77 SMN1; SMN2 (0.31) SMN1; SMN2
SCHEMBL8398133 0.77 SMN1; SMN2 (0.31) SMN1; SMN2
SCHEMBL7316609 0.77 CA1 (0.37) TSHR
SCHEMBL8397499 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120202243-A Thermosetting resin composition, cured film, substrate, and electronic component 捷恩智株式会社 2025-06-24 CN disclosed
US-20240026428-A1 METHODS FOR IN SITU TRANSCRIPTOMICS AND PROTEOMICS FIRST-CITIZENS BANK & TRUST COMPANY 2024-01-25 US disclosed
US-20240024490-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES THE BROAD INSTITUTE, INC. 2024-01-25 US disclosed
US-20230366013-A1 SPATIAL SEQUENCING FIRST-CITIZENS BANK & TRUST COMPANY 2023-11-16 US disclosed
US-20230242904-A1 HIGH DENSITY SEQUENCING AND MULTIPLEXED PRIMING FIRST-CITIZENS BANK & TRUST COMPANY 2023-08-03 US disclosed
US-20230203579-A1 NANOARRAYS AND METHODS OF USE THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2023-06-29 US disclosed
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF THE BROAD INSTITUTE, INC. 2023-06-22 US disclosed
US-20230145826-A1 FLUORESCENT LABELING AGENT AND FLUORESCENT DYE TOYO INK SC HOLDINGS CO., LTD. (JP) 2023-05-11 US disclosed
US-20230145826-A1 FLUORESCENT LABELING AGENT AND FLUORESCENT DYE TOYO INK SC HOLDINGS CO., LTD. (JP) 2023-05-11 US disclosed
US-20230111099-A1 HIGH DENSITY SEQUENCING AND MULTIPLEXED PRIMING FIRST-CITIZENS BANK & TRUST COMPANY 2023-04-13 US disclosed
WO-2009108566-A2 METHOD FOR REDUCING FOULING IN FURNACES BAKER HUGHES INCORPORATED (US) 2009-09-03 WO disclosed
WO-2008079784-A2 FUNCTIONALIZED OLEFIN POLYMERS, COMPOSITIONS AND ARTICLES PREPARED THEREFROM, AND METHODS FOR MAKING THE SAME DOW GLOBAL TECHNOLOGIES INC. (US) 2008-07-03 WO disclosed
WO-2008080111-A1 POLYOLEFIN COMPOSITIONS AND ARTICLES PREPARED THEREFROM, AND METHODS FOR MAKING THE SAME DOW GLOBAL TECHNOLOGIES INC. (US) 2008-07-03 WO disclosed
US-7205385-B2 magnetic resonance imaging agents; poly(amino acid-imaging agent) product can be obtained in high purity without a rigorous purification since all impurities are removed at the monomer synthesis stage GENERAL ELECTRIC COMPANY (US) 2007-04-17 US disclosed
US-7205385-B2 magnetic resonance imaging agents; poly(amino acid-imaging agent) product can be obtained in high purity without a rigorous purification since all impurities are removed at the monomer synthesis stage GENERAL ELECTRIC COMPANY (US) 2007-04-17 US disclosed
US-20050234416-A1 Nano-sized materials in hygiene products COGNIS IP MANAGEMENT GMBH (DE) 2005-10-20 US disclosed
US-20040033270-A1 Nano-sized zinc oxide in hygiene products COGNIS IP MANAGEMENT GMBH (DE) 2004-02-19 US disclosed
US-4885385-A INTENSE, COLORFAST, BLUE DYES FOR HYDROXY- OR POLYAMIDO-CONTAINING FIBERS HOECHST AKTIENGESELLSCHAFT (DE) 1989-12-05 US disclosed
US-4774333-A Water-soluble triphendioxazine compounds and sulfonyl-containing precursors thereof, processes for the preparation thereof and use of the triphendioxazines as dyes HOECHST AKTIENGESELLSCHAFT (DE) 1988-09-27 US disclosed
CN-86105939-A OPTICAL RESONANT ASSEMBLY 1987-07-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024490-A1 BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES COASY, JMJD7, PTMS SMN1; SMN2 3607/4885ALDH1A1 1238/4885TSHR 4141/4885
US-20230192904-A1 BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF ERBB2, ACP1, TK1 SMN1; SMN2 3469/4885ALDH1A1 2221/4885TSHR 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.